SCHEMBL9107951

SCHEMBL9107951

Cc1ccc(CC(C(=O)O)c2cccs2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.46
RAB9A P51151 4/20 0.44
SMN1; SMN2 Q16637 5/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 3/20 0.43
HTT P42858 1/20 0.43
NPC1 O15118 3/20 0.43
GAA P10253 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
MEN1 O00255 1/20 0.43
PKM P14618 1/20 0.43
ALOX15 P16050 1/20 0.43
KMT2A Q03164 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CYP2C19 P33261 1/20 0.42
POLB P06746 2/20 0.42
TRPM8 Q7Z2W7 1/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
KEAP1 Q14145 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27878871 0.87 POLB (0.50) RAB9ASMN1; SMN2ALDH1A1NPC1PKM
SCHEMBL9108692 0.85 POLB (0.44) TP53RAB9ASMN1; SMN2ALDH1A1MEN1
SCHEMBL6177780 0.84 LDHA (0.56) TP53RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL6006143 0.78 LMNA (0.45) TP53RAB9ASMN1; SMN2ALDH1A1NPC1
SCHEMBL6003700 0.78 LMNA (0.45) TP53RAB9ASMN1; SMN2ALDH1A1NPC1
SCHEMBL28770357 0.78 EPHX1 (0.46) RAB9ASMN1; SMN2ALDH1A1HPGDNPC1
SCHEMBL2071309 0.77 CYP2C19 (0.46) TP53RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL22394826 0.76 SMN1; SMN2 (0.56) SMN1; SMN2ALDH1A1MEN1KMT2ACYP2C19
SCHEMBL4215659 0.75 GLS (0.48) TP53RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL28607302 0.75 EPHX1 (0.60) RAB9ASMN1; SMN2ALDH1A1HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2646027-B1 NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN INC (US) 2014-10-15 EP disclosed
US-8697733-B2 Pyridine derivatives as sphingosine 1-phosphate (S1P) receptor modulators ALLERGAN, INC. (US) 2014-04-15 US disclosed
US-20130338195-A1 NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN, INC. 2013-12-19 US disclosed
US-8492410-B2 Pyridine derivatives as sphingosine 1-phosphate (S1P) receptor modulators ALLERGAN, INC. (US) 2013-07-23 US disclosed
US-20130150411-A1 NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-06-13 US disclosed
US-8399492-B2 Pyridine derivatives as sphingosine 1-phosphate (S1P) receptor modulators ALLERGAN, INC. (US) 2013-03-19 US disclosed
US-20120142736-A1 NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150411-A1 NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS S1PR1, S1PR3, S1PR2 TP53 4783/4885RAB9A 2172/4885SMN1; SMN2 3214/4885
US-20130338195-A1 NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS S1PR1, S1PR3, S1PR2 TP53 4783/4885RAB9A 2172/4885SMN1; SMN2 3214/4885
US-20120142736-A1 NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS S1PR1, S1PR3, S1PR2 TP53 4783/4885RAB9A 2172/4885SMN1; SMN2 3214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.